Zhejiang Huahai Pharmaceutical Co Ltd (600521) - Total Liabilities
Based on the latest financial reports, Zhejiang Huahai Pharmaceutical Co Ltd (600521) has total liabilities worth CN¥12.36 Billion CNY (≈ $1.81 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Huahai Pharmaceutical Co Ltd - Total Liabilities Trend (2000–2025)
This chart illustrates how Zhejiang Huahai Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Zhejiang Huahai Pharmaceutical Co Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Zhejiang Huahai Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Huahai Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kinik Co
TW:1560
|
Taiwan | NT$4.69 Billion |
|
Jiangsu Aucksun Co Ltd
SHE:002245
|
China | CN¥5.12 Billion |
|
Impinj Inc
NASDAQ:PI
|
USA | $335.95 Million |
|
Genscript Biotech Corporation
F:G51
|
Germany | €888.59 Million |
|
GPGI, Inc.
NYSE:GPGI
|
USA | $297.80 Million |
|
Dolby Laboratories
NYSE:DLB
|
USA | $591.27 Million |
|
AllianceBernstein Holding L.P.
NYSE:AB
|
USA | $1.87 Million |
|
MERCARI INC. UNSP.ADR/1/2
F:6TP0
|
Germany | €503.91 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Zhejiang Huahai Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 600521 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Huahai Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Huahai Pharmaceutical Co Ltd (2000–2025)
The table below shows the annual total liabilities of Zhejiang Huahai Pharmaceutical Co Ltd from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥12.05 Billion ≈ $1.76 Billion |
+7.17% |
| 2024-12-31 | CN¥11.24 Billion ≈ $1.64 Billion |
+8.62% |
| 2023-12-31 | CN¥10.35 Billion ≈ $1.51 Billion |
-0.55% |
| 2022-12-31 | CN¥10.41 Billion ≈ $1.52 Billion |
+19.72% |
| 2021-12-31 | CN¥8.69 Billion ≈ $1.27 Billion |
+38.70% |
| 2020-12-31 | CN¥6.27 Billion ≈ $917.01 Million |
+26.58% |
| 2019-12-31 | CN¥4.95 Billion ≈ $724.43 Million |
-19.64% |
| 2018-12-31 | CN¥6.16 Billion ≈ $901.51 Million |
+91.80% |
| 2017-12-31 | CN¥3.21 Billion ≈ $470.03 Million |
+49.50% |
| 2016-12-31 | CN¥2.15 Billion ≈ $314.40 Million |
+19.69% |
| 2015-12-31 | CN¥1.80 Billion ≈ $262.69 Million |
+44.31% |
| 2014-12-31 | CN¥1.24 Billion ≈ $182.03 Million |
-14.02% |
| 2013-12-31 | CN¥1.45 Billion ≈ $211.71 Million |
+14.14% |
| 2012-12-31 | CN¥1.27 Billion ≈ $185.49 Million |
+21.01% |
| 2011-12-31 | CN¥1.05 Billion ≈ $153.28 Million |
+42.33% |
| 2010-12-31 | CN¥735.92 Million ≈ $107.69 Million |
+40.72% |
| 2009-12-31 | CN¥522.98 Million ≈ $76.53 Million |
+26.17% |
| 2008-12-31 | CN¥414.51 Million ≈ $60.66 Million |
+44.04% |
| 2007-12-31 | CN¥287.78 Million ≈ $42.11 Million |
+29.25% |
| 2006-12-31 | CN¥222.66 Million ≈ $32.58 Million |
+28.92% |
| 2005-12-31 | CN¥172.70 Million ≈ $25.27 Million |
+56.97% |
| 2004-12-31 | CN¥110.03 Million ≈ $16.10 Million |
+23.25% |
| 2003-12-31 | CN¥89.27 Million ≈ $13.06 Million |
-46.75% |
| 2002-12-31 | CN¥167.62 Million ≈ $24.53 Million |
+10.48% |
| 2001-12-31 | CN¥151.72 Million ≈ $22.20 Million |
+34.52% |
| 2000-12-31 | CN¥112.79 Million ≈ $16.50 Million |
-- |
About Zhejiang Huahai Pharmaceutical Co Ltd
Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production and sales of generic drugs, biological drugs, and APIs in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as polyethylene bottles and pol… Read more